Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Open accessThe DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index; 41 of the 57 sources its claims cite were checked for support.
Abstract
Leber hereditary optic neuropathy (LHON) is an important example of mitochondrial blindness with the m.11778G>A mutation in the MT-ND4 gene being the most common disease-causing mtDNA variant worldwide. The REFLECT phase 3 pivotal study is a randomized, double-masked, placebo-controlled trial investigating the efficacy and safety of bilateral intravitreal injection of lenadogene nolparvovec in patients with a confirmed m.11778G>A mutation, using a recombinant adeno-associated virus vector 2, serotype 2 (rAAV2/2-ND4). The first-affected eye received gene therapy; the fellow (affected/not-yet-affected) eye was randomly injected with gene therapy or placebo. The primary end point was the difference in change from baseline of best-corrected visual acuity (BCVA) in second-affected/not-yet-affected eyes treated with lenadogene nolparvovec versus placebo at 1.5 years post-treatment, expressed in logarithm of the minimal angle of resolution (LogMAR). Forty-eight patients were treated bilaterally and 50 unilaterally. At 1.5 years, the change from baseline in BCVA was not statistically different between second-affected/not-yet-affected eyes receiving lenadogene nolparvovec and placebo (primary end point). A statistically significant improvement in BCVA was reported from baseline to 1.5 years in lenadogene nolparvovec-treated eyes: −0.23 LogMAR for the first-affected eyes of bilaterally treated patients (P < 0.01); and −0.15 LogMAR for second-affected/not-yet-affected eyes of bilaterally treated patients and the first-affected eyes of unilaterally treated patients (P < 0.05). The mean improvement in BCVA from nadir to 1.5 years was −0.38 (0.052) LogMAR and −0.33 (0.052) LogMAR in first-affected and second-affected/not-yet-affected eyes treated with lenadogene nolparvovec, respectively (bilateral treatment group). A mean improvement of −0.33 (0.051) LogMAR and −0.26 (0.051) LogMAR was observed in first-affected lenadogene nolparvovec-treated eyes and second-affected/not-yet-affected placebo-treated eyes, respectively (unilateral treatment group). The proportion of patients with one or both eyes on-chart at 1.5 years was 85.4% and 72.0% for bilaterally and unilaterally treated patients, respectively. The gene therapy was well tolerated, with no systemic issues. Intraocular inflammation, which was mostly mild and well controlled with topical corticosteroids, occurred in 70.7% of lenadogene nolparvovec-treated eyes versus 10.2% of placebo-treated eyes. Among eyes treated with lenadogene nolparvovec, there was no difference in the incidence of intraocular inflammation between bilaterally and unilaterally treated patients. Overall, the REFLECT trial demonstrated an improvement of BCVA in LHON eyes carrying the m.11778G>A mtDNA mutation treated with lenadogene nolparvovec or placebo to a degree not reported in natural history studies and supports an improved benefit/risk profile for bilateral injections of lenadogene nolparvovec relative to unilateral injections.
Overview
CoChat Summary
TL;DR
REFLECT, a phase 3 randomized, double-masked, placebo-controlled trial, tested bilateral intravitreal lenadogene nolparvovec in patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy. The primary endpoint comparing second-affected/not-yet-affected eyes treated with gene therapy versus placebo at 1.5 years was not met, although treated eyes improved and bilateral treatment showed better visual outcomes than unilateral treatment.
Key findings
- The primary endpoint was not met: the least squares mean difference in BCVA change from baseline to 1.5 years between second-affected/not-yet-affected lenadogene nolparvovec- and placebo-treated eyes was −0.05 LogMAR (P = 0.6080, ANCOVA), below the prespecified clinically significant difference of −0.3 LogMAR.
- In lenadogene nolparvovec-treated eyes, BCVA improved from baseline to 1.5 years: by linear mixed model, first-affected eyes of bilaterally treated patients improved −0.23 (0.070) LogMAR (+12 ETDRS letters, P < 0.01), while second-affected/not-yet-affected eyes of bilaterally treated patients and first-affected eyes of unilaterally treated patients each improved −0.15 LogMAR (+8 ETDRS letters, P < 0.05).
- From nadir to 1.5 years, all eye groups improved significantly (P < 0.0001); by linear mixed model, first-affected and second-affected/not-yet-affected eyes treated with lenadogene nolparvovec in the bilateral group improved −0.38 (0.052) and −0.33 (0.052) LogMAR, respectively, while first-affected lenadogene-treated and second-affected placebo-treated eyes in the unilateral group improved −0.33 (0.051) and −0.26 (0.051) LogMAR.
- Intraocular inflammation occurred in 70.7% of lenadogene nolparvovec-treated eyes versus 10.2% of placebo-treated eyes, was mostly mild and controlled with topical corticosteroids, and did not differ in incidence between bilaterally and unilaterally treated patients among gene-therapy eyes; no systemic life-threatening AEs, deaths, or serious ocular AEs were reported.
Methods
- Phase 3, pivotal, randomized, double-masked, placebo-controlled study at 13 centres in seven countries; 98 patients with m.11778G>A MT-ND4 LHON and vision loss ≤1 year were randomized 1:1 to bilateral treatment (48 patients) or unilateral treatment (50 patients).
- In both arms, the first-affected eye received lenadogene nolparvovec; the second-affected/not-yet-affected eye was randomized to lenadogene nolparvovec or placebo (balanced salt solution). Dose was 9 × 10^10 vector genomes in 90 µl per eye.
- Primary endpoint was the difference in change from baseline to 1.5 years in LogMAR BCVA between second-affected/not-yet-affected lenadogene- and placebo-treated eyes; analyses used ANCOVA and a prespecified linear mixed model sensitivity analysis in SAS v9.4.
Limitations
- The paper states that the contralateral effect in unilaterally treated patients means contralateral placebo/sham eyes are not appropriate controls; the lack of a patient placebo-controlled arm requires indirect comparison with published natural history data, which were not prospective and had inconsistent data acquisition.
- The paper also states that the baseline BCVA primary endpoint is problematic because disease onset ranged within 12 months and baseline BCVA was inhomogeneous; nadir BCVA may be a more clinically relevant reference, though eyes can only improve from nadir.
- The text makes evident that the primary endpoint was not met and that improvements in treated eyes are partly interpreted against natural history rather than a randomized untreated control; possible eccentric fixation contribution is also noted by the authors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 3 Not valid · 10 Not checked · 139 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The dose of lenadogene nolparvovec selected in REFLECT (9 × 1010 vg/eye) was the maximal tolerated dose determined in the previous phase 1/2a REVEAL study.15,21”
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Materials and methods > Study design
What the sources say
- Partly supportedcites [15] Vignal, 2018, Safety of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy, Ophthalmology sourceExperimental — accuracy not yet measured
The trial description (page unavailable) confirms that the Phase I/II study tested 9 × 10^10 vg/eye and used that dose for an extension cohort. It does not identify that dose as the maximal tolerated dose or say it was selected for REFLECT; it also reports testing a higher dose of 1.8 × 10^11 vg/eye. (LLM, conf=0.84)
- Supportedcites [21] Vignal-Clermont, 2021, Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: The REVEAL study, Biodrugs source
The Discussion states that REVEAL was a dose-finding trial and that 9 × 10^10 vg/eye was selected as the maximum tolerated dose for pivotal phase III studies. The Materials and Methods identify REVEAL as a phase I/IIa trial. The cited passage does not name REFLECT, but it directly supports the dose-selection point attributed to REVEAL. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Retinal ganglion cells (RGCs), whose axons form the optic nerve, are the major cellular target affected by the resultant mitochondrial dysfunction.1”
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Introduction
What the sources say
- Supportedcites [1] Carelli, 2017, International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy, J Neuroophthalmol source
The Introduction states that LHON-associated mitochondrial DNA mutations affect complex I genes and that LHON leads to selective degeneration of retinal ganglion cells. It also describes the axons of macular RGCs as forming the papillomacular bundle, supporting the claim that RGCs are the principal cellular target. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The GCL macular volume measurements displayed a similar relationship with final BCVA groups in RESCUE and REVERSE.15,18”
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Discussion
What the sources say
- Could not verifycites [15] Vignal, 2018, Safety of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy, Ophthalmology sourceExperimental — accuracy not yet measured
In the paper’s concluding section (page not available), RESCUE and REVERSE are described as ongoing studies, not as studies with reported final BCVA groups. A search for GCL or ganglion-cell-layer macular volume and its relationship to final BCVA found no passage addressing the claimed relationship. (LLM, conf=0.76)
- Could not verifycites [18] Newman, 2021, Intravitreal gene therapy versus. Natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G>A ND4 mutation: Systematic review and indirect comparison, Front Neurol sourceExperimental — accuracy not yet measured
The Comparison of Visual Acuities at Last Available Observation section reports BCVA results for RESCUE and REVERSE, but does not relate them to GCL macular volume or final BCVA groups. Searches for “GCL,” “ganglion cell layer,” and “macular volume” found no passage addressing that relationship. Page numbers were not available in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This relationship was also demonstrated in both RESCUE and REVERSE and further illustrates the remarkable coherence in efficacy results for all three studies.15,18”
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Discussion
What the sources say
- Could not verifycites [15] Vignal, 2018, Safety of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy, Ophthalmology sourceExperimental — accuracy not yet measured
The paper’s concluding passage describes RESCUE and REVERSE as ongoing studies expected to inform visual-outcome trends; it does not report their results. Although its methods list Humphrey Visual Field testing and BCVA, searches for HVF mean deviation and its relationship to final BCVA found no analysis demonstrating the claimed relationship in either trial. The indexed passages provide no page numbers. (LLM, conf=0.78)
- Could not verifycites [18] Newman, 2021, Intravitreal gene therapy versus. Natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G>A ND4 mutation: Systematic review and indirect comparison, Front Neurol sourceExperimental — accuracy not yet measured
The 'Comparison of Visual Acuities at Last Available Observation' section reports BCVA outcomes separately for RESCUE and REVERSE, but not a relationship between change in HVF mean deviation and final BCVA. Searches for HVF, mean deviation, and visual field found no passage in our copy demonstrating that relationship; page numbers were not available. (LLM, conf=0.76)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two similar gene therapy programmes led by groups in the USA25,26 and China,27–30 have targeted the m.11778G>A mutation in MT-ND4, also using a viral vector containing a cDNA coding the human wild-type mitochondrial ND4 protein.”
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Discussion
What the sources say
- Supportedcites [25] Feuer, 2016, Gene therapy for Leber hereditary optic neuropathy: Initial results, Ophthalmology source
The Purpose passage describes a US gene-therapy trial for patients with the G11778A ND4 mutation using an AAV vector expressing normal ND4 cDNA. The Methods passage identifies the vector and its recoded ND4 insert. The China programme has separate citations in the citing sentence, so its details are not attributed to this source. (LLM, conf=0.93)
- Supportedcites [26] Guy, 2017, Gene therapy for Leber hereditary optic neuropathy: Low- and medium-dose visual results, Ophthalmology source
The Introduction (page unavailable) describes this US programme as treating G11778A LHON with a recoded ND4 gene inserted into an adeno-associated viral vector. The paper also states that the vector contained a normal nuclear-encoded ND4 gene. In the citing sentence, the USA citations support the US programme; separate citations accompany the China programme. (LLM, conf=0.92)
- Supportedcites [27] Wan, 2016, Efficacy and safety of rAAV2-ND4 treatment for Leber’s hereditary optic neuropathy, Sci Rep source
The Abstract and Methods (Study design) describe this study’s AAV2-ND4 gene therapy for patients carrying the G11778A mutation. Methods (Construction of the rAAV plasmid) describes a viral vector containing a synthesized DNA sequence coding for ND4. This source supports the China programme to which it is cited; the separate USA programme is attributed to other citations. (LLM, conf=0.88)
- Supportedcites [28] Yang, 2016, Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy, EBioMedicine source
The Abstract (page not available) identifies the Chinese programme’s target as the 11778 G-to-A mutation and reports treatment with an adeno-associated viral vector carrying ND4. The Methods section, “Recombinant adeno-associated virus” (page not available), describes modifying the mitochondrial ND4 sequence for expression of normal ND4 protein. This supports the part of the sentence attributed to the Chinese programme; the separate USA citations are not being judged here. (LLM, conf=0.88)
- Partly supportedcites [29] Liu, 2020, Factors associated with rapid improvement in visual acuity in patients with Leber’s hereditary optic neuropathy after gene therapy, Acta Ophthalmol (Copenh) sourceExperimental — accuracy not yet measured
The Study participants section (page unavailable) describes a trial in China treating patients with the MT-ND4 m.11778G>A mutation by injecting AAV2-ND4. The Discussion says the introduced ND4 gene produces functional protein that replaces defective ND4, but our copy does not specify that the vector contains a cDNA coding the human wild-type protein. The separate citations attached to the US programmes are outside this source's attribution. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [30] Yuan, 2018, Visual field variability after gene therapy for Leber’s hereditary optic neuropathy, Ophthalmic Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
99 more claims · 4 with their cited sources checked
Create a free account to see all 169 claims and every source verdict.
- It may state two separate claims as one. 58
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This inflammation could lead to secondary cataract or raised intraocular pressure if poorly controlled (Comander et al., 2016; Newman et al., 2023).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Newman et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The REVERSE (NCT02652780), RESCUE (NCT02652767), and REFLECT (NCT03293524) Phase III studies in LHON all reported a similar inci dence of intraocular inflammation with the same construct and dose of AAV vector despite different prophylaxis regimes.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Newman et al., 2023
Experimental — accuracy not yet measuredIn the citing paper
“Bilateral injection of lenadogene nolparvovec (an AAV-engineered allotopic ND4 gene) in the eyes of LHON patients carrying the m.11778G>A MT-ND4 mutation improved visual acuity and has shown excellent safety profile.41”
From Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo (2024) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Results > Efficacy data
“Similarly, as for the HVF MD, subgroup analyses were performed to investigate the relationship between GCL macular volume and final BCVA at 1.5 years post-treatment.”
§ Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy > Results > Efficacy data
“The relationship between change from baseline of HVF MD and final BCVA subgroups is shown in Supplementary Fig. 4.”
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440 · cited 1×
“especially onset at less than 12 years, portends a relatively better visual prognosis.(2,3,6)”
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“latory agencies for an inherited retinal degenerative disorder, Leber congenital amaurosis caused by biallelic RPE65 mutations.(7) Gene”
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
THE DESIGN OF A NEW LETTER CHART FOR MEASURING CONTRAST SENSITIVITY
Pelli, D. G., Robson, J. G., & Wilkins, A. J. (1988) · Cited by 1,308
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633 · cited 1×
“A primary mtDNA mutation is necessary, but not sufficient to cause vision loss, as there is well-documented incomplete penetrance with 20– 50% of male and 4–20% of female carriers manifesting the clinical disease during their lifetime.(5) The m.”
Self-citationAAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
BARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247
Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232 · cited 7×
“The physiologic basis of the contralateral effect of unilateral lenadogene nolparvovec IVT has been investigated in a mechanistic study conducted in non-human primates.(16,33) This study suggested there is some transfer of viral vector DNA from the injected eyes to the uninjected contralateral eyes after unilateral le…”
InfluentialSelf-citationCsaky, K., Ferris, F., Chew, E. Y., Nair, P., Cheetham, J. K., & Duncan, J. L. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22339 · Cited by 231
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Carelli, V., Carbonelli, M., de Coo, I. F., Kawasaki, A., Klopstock, T., Lagrèze, W. A., La Morgia, C., Newman, N. J., Orssaud, C., Pott, J. W. R., et al. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000570 · Cited by 228 · cited 3×
“4 A primary mtDNA mutation is necessary, but not sufficient to cause vision loss, as there is well-documented incomplete penetrance with 20– 50% of male and 4–20% of female carriers manifesting the clinical disease during their lifetime.5 The m.11778G>A mutation is the most common LHON mutation, accounting for about 7…”
Self-citationBarboni, P., Carbonelli, M., Savini, G., Ramos, C. D. V. F., Carta, A., Berezovsky, A., Salomao, S. R., Carelli, V., & Sadun, A. A. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.07.026 · Cited by 215
Self-citationGene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
A neurodegenerative perspective on mitochondrial optic neuropathies
Yu-Wai-Man, P., Votruba, M., Burté, F., La Morgia, C., Barboni, P., & Carelli, V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1625-2 · Cited by 176 · cited 4×
“4 A primary mtDNA mutation is necessary, but not sufficient to cause vision loss, as there is well-documented incomplete penetrance with 20– 50% of male and 4–20% of female carriers manifesting the clinical disease during their lifetime.5 The m.11778G>A mutation is the most common LHON mutation, accounting for about 7…”
InfluentialSelf-citationNewman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
Self-citationSavini, G., Barboni, P., Valentino, M. L., Montagna, P., Cortelli, P., DeNegri, A. M., Sadun, F., BIANCHI, S., Longanesi, L., Zanini, M., et al. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.09.033 · Cited by 153
Hellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142 · cited 3×
“This relationship was also demonstrated in both RESCUE and REVERSE and further illustrates the remarkable coherence in efficacy results for all three studies.15,18 OCT has proven to be an important tool in evaluating the clinical course of LHON.4,34–38 In our analyses, among the parameters measured by OCT, the GCL mac…”
InfluentialLong-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
Bonnet, C., Augustin, S., Ellouze, S., Bénit, P., Bouaita, A., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.04.018 · Cited by 130 · cited 1×
“struct includes the cis-acting elements of the human cytochrome c oxidase 10 (COX10) mtRNA (MTS in 5′ of the cDNA, and 3′ UTR at the 3′ end of the cDNA) ensuring the efficient delivery of the corresponding hybrid mRNA to the mitochondrial surface.(12,13)”
Self-citationClinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations
Pfeffer, G., Burke, A., Yu-Wai-Man, P., Compston, D. A. S., & Chinnery, P. F. (2013) · Neurology · doi:10.1212/01.wnl.0000437308.22603.43 · Cited by 122
Self-citationMathematically Modeling the Involvement of Axons in Leber's Hereditary Optic Neuropathy
Pan, B. X., Ross-Cisneros, F. N., Carelli, V., Rue, K. S., Salomao, S. R., Moraes-Filho, M. N., Moraes, M. N., Berezovsky, A., Belfort, R., & Sadun, A. A. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10452 · Cited by 120
Self-citationNewman, N. J., Carelli, V., Taiel, M., & Yu-Wai-Man, P. (2020) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001045 · Cited by 111 · cited 4×
“4 A primary mtDNA mutation is necessary, but not sufficient to cause vision loss, as there is well-documented incomplete penetrance with 20– 50% of male and 4–20% of female carriers manifesting the clinical disease during their lifetime.5 The m.11778G>A mutation is the most common LHON mutation, accounting for about 7…”
InfluentialSelf-citationMacular nerve fibre and ganglion cell layer changes in acute Leber's hereditary optic neuropathy
Balducci, N., Savini, G., Cascavilla, M. L., Morgia, C. L., Triolo, G., Giglio, R., Carbonelli, M., Parisi, V., Sadun, A. A., Bandello, F. M., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307326 · Cited by 109
Self-citationSafety of rAAV2/2-ND4 gene therapy for leber hereditary optic neuropathy
Vignal, C., Uretsky, S., Fitoussi, S., Galy, A., Blouin, L., Girmens, J.-F., Bidot, S., Thomasson, N., Bouquet, C., Valero, S., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.036 · Cited by 99 · cited 5×
“The GCL macular volume measurements displayed a similar relationship with final BCVA groups in RESCUE and REVERSE.(15,18)”
InfluentialSelf-citationBonnet, C., Kaltimbacher, V., Ellouze, S., Augustin, S., Bénit, P., Forster, V., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2007) · Rejuvenation Research · doi:10.1089/rej.2006.0526 · Cited by 98 · cited 1×
“struct includes the cis-acting elements of the human cytochrome c oxidase 10 (COX10) mtRNA (MTS in 5′ of the cDNA, and 3′ UTR at the 3′ end of the cDNA) ensuring the efficient delivery of the corresponding hybrid mRNA to the mitochondrial surface.(12,13)”
Self-citationNewman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97 · cited 2×
“especially onset at less than 12 years, portends a relatively better visual prognosis.(2,3,6)”
Self-citationLam, B. L., Feuer, W. J., Schiffman, J. C., Porciatti, V., Vandenbroucke, R., Rosa, P. R., Gregori, G., & Guy, J. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7971 · Cited by 96 · cited 1×
“inconclusive results when compared to their equally limited prospective natural history study.(32)”
Cwerman-Thibault, H., Augustin, S., Lechauve, C., Ayache, J., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.3 · Cited by 86
Self-citationBiousse, V., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001367 · Cited by 78 · cited 5×
“Patients who completed the RESCUE and REVERSE studies are being followed in the ongoing extension study, RESTORE, and results at 3 years posttreatment have been reported.(20)”
InfluentialSelf-citationKoilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15388 · Cited by 65
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Biousse, V., Moster, M. L., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Girmens, J.-F., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.662838 · Cited by 64 · cited 9×
“eral response seen in both treated and sham eyes in REVERSE and RESCUE, and to a degree not reported in natural history studies of LHON patients of corresponding age and genotype.(18) Further evidence of a contralateral effect among unilaterally treated REFLECT patients can be found in the time course of mean LogMAR B…”
InfluentialSelf-citationVignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A. (2021) · BioDrugs · doi:10.1007/s40259-021-00468-9 · Cited by 51 · cited 1×
“The dose of lenadogene nolparvovec selected in REFLECT (9 × 10(10) vg/eye) was the maximal tolerated dose determined in the previous phase 1/2a REVEAL study.(15,21) This dose was also selected in the phase 3 studies RESCUE and REVERSE.”
Self-citationKoilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48
Moster, S. J., Moster, M. L., Scannell Bryan, M., & Sergott, R. C. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-17328 · Cited by 47 · cited 2×
“Moster et al.39 showed that GCL thickness has a stronger relationship to BCVA than other OCT measurements.”
Self-citationLam, B. L., Feuer, W. J., Davis, J. L., Porciatti, V., Yu, H., Levy, R. B., Vanner, E., & Guy, J. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.023 · Cited by 43 · cited 2×
“Indeed, the recent full results of the phase 1/2 study conducted by Lam et al.31 confirmed bilateral improvement in both injected and fellow eyes, although, as the authors themselves emphasize, the low number of patients provided limited power to assess efficacy of the gene therapy and inconclusive results when compar…”
[33] Allotopic expression of mitochondrial ATP synthase genes in nucleus of Saccharomyces cerevisiae
Gray, R. E., Law, R. H. P., Devenish, R. J., & Nagley, P. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)64035-x · Cited by 43 · cited 1×
“of the wild-type mitochondrial gene engineered with an additional mitochondrial targeting sequence (MTS) and results in mRNA translation and co-translocation of the protein into mitochondria.(8)”
Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Calkins, D. J., Yu-Wai-Man, P., Newman, N. J., Taiel, M., Singh, P., Chalmey, C., Rogue, A., Carelli, V., Ancian, P., & Sahel, J. A. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.013 · Cited by 37 · cited 2×
“The physiologic basis of the contralateral effect of unilateral lenadogene nolparvovec IVT has been investigated in a mechanistic study conducted in non-human primates.(16,33) This study suggested there is some transfer of viral vector DNA from the injected eyes to the uninjected contralateral eyes after unilateral le…”
Self-citationLiu, H., Yuan, J., Zhang, Y., Tian, Z., Li, X., Wang, D., Du, Y., Song, L., & Li, B. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14379 · Cited by 35
Ratra, D., Gopalakrishnan, S., Dalan, D., Ratra, V., Damkondwar, D., & Laxmi, G. (2019) · Clinical and Experimental Optometry · doi:10.1111/cxo.12834 · Cited by 29 · cited 1×
“ation as has been documented in patients with central scotomas from macular disease.(46)”
Visual field variability after gene therapy for Leber’s hereditary optic neuropathy
Yuan, J.-J., Zhang, Y., Wang, L.-L., Cheng, M.-S., Ma, S.-Q., Gao, Q., & Li, B. (2018) · Ophthalmic Research · doi:10.1159/000487485 · Cited by 17
Moster, M. L., Sergott, R. C., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Bryan, M. S., Smits, G., Biousse, V., Vignal-Clermont, C., Klopstock, T., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001316 · Cited by 7
Self-citation
Cited by
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Belgrad, J., Fakih, H. H., & Khvorova, A. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0068 · Cited by 142
“For example, in a Leber Hereditary Optic Neuropathy trial using an adeno-associated virus-based gene therapy, the therapy failed to meet clinical endpoints, but select patients are still being dosed to positive impacts (NCT02161380) [132].”
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 102
DB-OTO Gene Therapy for Inherited Deafness
Valayannopoulos, V., Bance, M., Carvalho, D., Greinwald, J. H., Harvey, S. A., Ishiyama, A., Landry, E. C., Löwenheim, H., Lustig, L. R., Manrique, M. J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2400521 · Cited by 76
Engineered mitochondria in diseases: mechanisms, strategies, and applications
Li, M., Wu, L., Si, H., Wu, Y., Liu, Y., Zeng, Y., & Shen, B. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02081-y · Cited by 79
Mitochondria in Retinal Ganglion Cells: Unraveling the Metabolic Nexus and Oxidative Stress
Yang, T.-H., Kang, E. Y., Lin, P., Yu, B. B.-C., Wang, J. H.-H., Chen, V., & Wang, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168626 · Cited by 67
“Lenadogene nolparvovec, administered via intravitreal injection, uses a recombinant adeno-associated virus vector (rAAV2/2-ND4) carrying the wild-type ND4 subunit of complex I to target mitochondria [240].”
BackgroundMethod
Metadata
- Authors
- Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Sadun, A. A., Rebolleda Fernández, G., Chwalisz, B. K., Banik, R., Bazin, F., Roux, M., Cox, E. D., Taiel, M., Sahel, J.-A., the LHON REFLECT Study Group, Giulia, A., Shweta, A., Rudrani, B., Piero, B., Valérie, B., Hayley, B., Asma, B., Michele, C., Valerio, C., Celia, C., Hui-Chen, C., Steve, C., Chwalisz, B. K., Manuela, C., Pietro, D., DeBusk, A. A., Julie, D. Z., Jannah, D., Donahue, S. P., Lindreth, D., Simona, E., Alcides, F. F., Elizabeth, F., Sapna, G., Deborah, G., François, G. J., Rabih, H., Haller, J. A., Gad, H., George Baker, H. I., Jeong-Min, H., Laia, J. U., Neringa, J., Rustum, K., Wahiba, K., La Chiara, M., Leroy, B. P., Maria, M., Marc, M., Memon, M. A., Susan, M., Moster, M. L., Muñoz Negrete, F. J., Newman, N. J., Ghazala, O., Shriji, P., Paula, P., Peragallo, J. H., Lise, P., Mary, P., Gema, R. F., Martina, R., Sadun, A. A., José-Alain, S., Melissa, S., Sergott, R. C., Subramanian, P. S., Chuanbin, S., Katy, T., Heather, T., Irena, T., Tucker, W. R., Catherine, V.-C., An-Guor, W., Saige, W., & Patrick, Y.-W.-M.
- Affiliations
- Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge , Cambridge , UK
- Department of Ophthalmology, Taipei Veterans General Hospital, National Yang Ming Chiao Tung University , Taipei , Taiwan
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica , Bologna , Italy
- Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine , Atlanta, GA , USA
- Department of Neuro Ophthalmology and Emergencies, Rothschild Foundation Hospital , Paris , France
- Department of Ophthalmology, Alcala University , Madrid , Spain
- Department of Ophthalmology, Icahn School of Medicine at Mount Sinai , New York, NY , USA
- eXYSTAT, Data Management and Statistics , Paris , France
- GenSight Biologics (France) (FR)
- Sorbonne Université, INSERM, CNRS, Institut de la Vision , Paris , France
- Emory University (US)
- Centre hospitalier national d'ophtalmologie des Quinze-Vingts (FR)
- University of Cambridge (GB)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-09
- Volume
- 146
- Issue
- 4
- Pages
- 1328-1341
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10115230
- OpenAlex
- W4308638146
- Semantic Scholar
- 7d606d45682e951aa6595bd553df517cdbb841e2
- Cited by
- 87
- References
- 48
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 29 · 2023: 11 · 2022: 3
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- GenSight Biologics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- Leber's hereditary optic neuropathy, m.11778G>A mutation, MT-ND4, intravitreal injection, best-corrected visual acuity, REFLECT trial, recombinant adeno-associated virus vectors, gene therapy
- MeSH terms
- Dependovirus, DNA, Mitochondrial, Humans, Inflammation, Mutation, NADH Dehydrogenase, Genetic Therapy, Optic Atrophy, Hereditary, Leber
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.